Immunization with apoptotic pseudovirus transduced cells induces both cellular and humoral responses: A proof of concept study in macaques

Vaccine

Volumn 30, Issue 15, 2012, Pages 2523-2534

  Koopman, Gerrit ^a   Beenhakker, Niels ^a   Hofman, Sam ^a   Walther Jallow, Lilian ^b   Mäkitalo, Barbro ^b   Mooij, Petra ^a   Anderson, Jan ^b   Verschoor, Ernst ^a   Bogers, Willy M J ^a   Heeney, Jonathan L ^a,c   Spetz, Anna Lena ^b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Apoptotic cell; B cells; Immunogenicity; SIV; T cells

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; KI 67 ANTIGEN; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SAFETY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS GENE; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, CD4; APOPTOSIS; CELL LINE; DEFECTIVE VIRUSES; EPITOPES; GENE PRODUCTS, GAG; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; KI-67 ANTIGEN; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRAL LOAD;

EID: 84862829085     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.082     Document Type: Article

References (78)

1. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392:86-89.
2. Larsson M., Fonteneau J.F., Somersan S., Sanders C., Bickham K., Thomas E.K., et al. Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol 2001, 31:3432-3442.
3. Larsson M., Fonteneau J.F., Lirvall M., Haslett P., Lifson J.D., Bhardwaj N. Activation of HIV-1 specific CD4 and CD8T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. AIDS 2002, 16:1319-1329.
4. Zhao X.Q., Huang X.L., Gupta P., Borowski L., Fan Z., Watkins S.C., et al. Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4- infected apoptotic cells. J Virol 2002, 76:3007-3014.
5. Schaible U.E., Winau F., Sieling P.A., Fischer K., Collins H.L., Hagens K., et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003, 9:1039-1046.
6. Subklewe M., Paludan C., Tsang M.L., Mahnke K., Steinman R.M., Munz C. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells. J Exp Med 2002, 193:405-411.
7. Arrode G., Boccaccio C., Lule J., Allart S., Moinard N., Abastado J.P., et al. Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells. J Virol 2000, 74:10018-10024.
8. den Haan J.M., Bevan M.J. Antigen presentation to CD8(+) T cells: cross-priming in infectious diseases. Curr Opin Immunol 2001, 13:437-441.
9. Maranon C., Desoutter J.F., Hoeffel G., Cohen W., Hanau D., Hosmalin A. Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes. Proc Natl Acad Sci USA 2004, 101:6092-6097.
10. Spetz A.L., Patterson B.K., Lore K., Andersson J., Holmgren L. Functional gene transfer of HIV DNA by an HIV receptor-independent mechanism. J Immunol 1999, 163:736-742.
11. Holmgren L., Szeles A., Rajnavolgyi E., Folkman J., Klein G., Ernberg I., et al. Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood 1999, 93:3956-3963.
12. Bergsmedh A., Szeles A., Henriksson M., Bratt A., Folkman M.J., Spetz A.L., et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA 2001, 98:6407-6411.
13. Taylor J., Meignier B., Tartaglia J., Languet B., VanderHoeven J., Franchini G., et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 1995, 13:539-549.
14. Egan M.A., Pavlat W.A., Tartaglia J., Paoletti E., Weinhold K.J., Clements M.L., et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 1995, 171:1623-1627.
15. Ignatius R., Marovich M., Mehlhop E., Villamide L., Mahnke K., Cox W.I., et al. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J Virol 2000, 74:11329-11338.
16. Motta I., Andre F., Lim A., Tartaglia J., Cox W.I., Zitvogel L., et al. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol 2001, 167:1795-1802.
17. Fadok V.A., Bratton D.L., Konowal A., Freed P.W., Westcott J.Y., Henson P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998, 101:890-898.
18. Bittencourt M.C., Perruche S., Contassot E., Fresnay S., Baron M.H., Angonin R., et al. Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. Blood 2001, 98:224-230.
19. Johansson U., Walther-Jallow L., Smed-Sorensen A., Spetz A.L. Triggering of dendritic cell responses after exposure to activated, but not resting, apoptotic PBMCs. J Immunol 2007, 179:1711-1720.
20. Johansson U., Walther-Jallow L., Hofmann A., Spetz A.L. Dendritic cells are able to produce IL-12p70 after uptake of apoptotic cells. Immunobiology 2011, 216:251-255.
21. Torchinsky M.B., Garaude J., Martin A.P., Blander J.M. Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature 2009, 458:78-82.
22. Liu M.A. Immunologic basis of vaccine vectors. Immunity 2010, 33:504-515.
23. Sarukhan A., Camugli S., Gjata B., von Boehmer H., Danos O., Jooss K. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol 2001, 75:269-277.
24. Schulz O., Diebold S.S., Chen M., Naslund T.I., Nolte M.A., Alexopoulou L., et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433:887-892.
25. Gasteiger G., Kastenmuller W., Ljapoci R., Sutter G., Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 2007, 81:11925-11936.
26. Kurts C., Robinson B.W., Knolle P.A. Cross-priming in health and disease. Nat Rev Immunol 2010, 10:403-414.
27. Tesniere A., Apetoh L., Ghiringhelli F., Joza N., Panaretakis T., Kepp O., et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008, 20:504-511.
28. Hege K.M., Jooss K., Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006, 25:321-352.
29. Luckashenak N., Schroeder S., Endt K., Schmidt D., Mahnke K., Bachmann M.F., et al. Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity 2008, 28:521-532.
30. Schnell T., Foley P., Wirth M., Munch J., Uberla K. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 2000, 11:439-447.
31. Smed-Sorensen A., Lore K., Walther-Jallow L., Andersson J., Spetz A.L. HIV-1-infected dendritic cells up-regulate cell surface markers but fail to produce IL-12 p70 in response to CD40 ligand stimulation. Blood 2004, 104:2810-2817.
32. Koopman G., Mortier D., Hofman S., Mathy N., Koutsoukos M., Ertl P., et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J Gen Virol 2008, 89:540-553.
33. Mooij P., Balla-Jhagjhoorsingh S.S., Koopman G., Beenhakker N., van Haaften P., Baak I., et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 2008, 82:2975-2988.
34. Bogers W.M., Davis D., Baak I., Kan E., Hofman S., Sun Y., et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008, 382:217-225.
35. Leutenegger C.M., Higgins J., Matthews T.B., Tarantal A.F., Luciw P.A., Pedersen N.C., et al. Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Res Hum Retroviruses 2001, 17:243-251.
36. Corrigan G.E., Hansson E.O., Morner A., Berry N., Kallander C.F., Thorstensson R. Reverse transcriptase viral load correlates with RNA in SIV/SHIV-infected macaques. AIDS Res Hum Retroviruses 2006, 22:917-923.
37. Bogers W.M., Niphuis H., ten Haaft P., Laman J.D., Koornstra W., Heeney J.L. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. Aids 1995, 9:F13-F18.
38. Koopman G., Mortier D., Hofman S., Niphuis H., Fagrouch Z., Norley S., et al. Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens. J Gen Virol 2004, 85:2915-2924.
39. Veazey R.S., Mansfield K.G., Tham I.C., Carville A.C., Shvetz D.E., Forand A.E., et al. Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol 2000, 74:11001-11007.
40. Spetz A.L., Sorensen A.S., Walther-Jallow L., Wahren B., Andersson J., Holmgren L., et al. Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells. J Immunol 2002, 169:5771-5779.
41. Brave A., Johansson U., Hallengard D., Heidari S., Gullberg H., et al. Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes. Vaccine 2010, 28:2080-2087.
42. Bruhl P., Kerschbaum A., Zimmermann K., Eibl M.M., Mannhalter J.W. Allostimulated lymphocytes inhibit replication of HIV type 1. AIDS Res Hum Retroviruses 1996, 12:31-37.
43. Peters B., Whittall T., Babaahmady K., Gray K., Vaughan R., Lehner T. Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection. Lancet 2004, 363:518-524.
44. Hinkula J., Walther-Jallow L., Lauren A., Makitalo B., Oberg M., et al. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells. Vaccine 2009, 27:6424-6431.
45. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010, 28:413-444.
46. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
47. Mir K.D., Gasper M.A., Sundaravaradan V., Sodora D.L. SIV infection in natural hosts: resolution of immune activation during the acute-to-chronic transition phase. Microbes Infect 2011, 13:14-24.
48. Giorgi J.V., Hultin L.E., McKeating J.A., Johnson T.D., Owens B., Jacobson L.P., et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999, 179:859-870.
49. Hazenberg M.D., Stuart J.W., Otto S.A., Borleffs J.C., Boucher C.A., de Boer R.J., et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000, 95:249-255.
50. Hazenberg M.D., Otto S.A., van Benthem B.H., Roos M.T., Coutinho R.A., Lange J.M., et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. Aids 2003, 17:1881-1888.
51. Wilson N.A., Keele B.F., Reed J.S., Piaskowski S.M., MacNair C.E., Bett A.J., et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 2009, 83:6508-6521.
52. Giraldo-Vela J.P., Bean A.T., Rudersdorf R., Wallace L.T., Loffredo J.T., Erickson P., et al. Simian immunodeficiency virus-specific CD4+ T cells from successful vaccinees target the SIV Gag capsid. Immunogenetics 2010, 62:701-707.
53. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13:46-53.
54. Novitsky V., Gilbert P., Peter T., McLane M.F., Gaolekwe S., Rybak N., et al. Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol 2003, 77:882-890.
55. Riviere Y., McChesney M.B., Porrot F., Tanneau-Salvadori F., Sansonetti P., Lopez O., et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 1995, 11:903-907.
56. Rolland M., Heckerman D., Deng W., Rousseau C.M., Coovadia H., Bishop K., et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 2008, 3:e1424.
57. Zitvogel L., Kroemer G. The immune response against dying tumor cells: avoid disaster, achieve cure. Cell Death Differ 2008, 15:1-2.
58. Griffith T.S., Yu X., Herndon J.M., Green D.R., Ferguson T.A. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996, 5:7-16.
59. Fadok V.A., Bratton D.L., Henson P.M. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 2001, 108:957-962.
60. Steinman R.M., Turley S., Mellman I., Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000, 191:411-416.
61. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000, 191:423-434.
62. Green D.R., Ferguson T., Zitvogel L., Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009, 9:353-363.
63. Ravichandran K.S. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med 2010, 207:1807-1817.
64. Najera J.L., Gomez C.E., Domingo-Gil E., Gherardi M.M., Esteban M. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 2006, 80:6033-6047.
65. Zhang X., Cassis-Ghavami F., Eller M., Currier J., Slike B.M., Chen X., et al. Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors. J Virol 2007, 81:7022-7033.
66. Sun R., Skeiky Y.A., Izzo A., Dheenadhayalan V., Imam Z., Penn E., et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27:4412-4423.
67. Reimann J., Schirmbeck R. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol Rev 1999, 172:131-152.
68. Chahroudi A., Garber D.A., Reeves P., Liu L., Kalman D., Feinberg M.B. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol 2006, 80:8469-8481.
69. Kim E.Y., Veazey R.S., Zahn R., McEvers K.J., Baumeister S.H., Foster G.J., et al. Contribution of CD8+ T cells to containment of viral replication and emergence of mutations in Mamu-A*01-restricted epitopes in Simian immunodeficiency virus-infected rhesus monkeys. J Virol 2008, 82:5631-5635.
70. Sun Y., Permar S.R., Buzby A.P., Letvin N.L. Memory CD4+ T-lymphocyte loss and dysfunction during primary simian immunodeficiency virus infection. J Virol 2007, 81:8009-8015.
71. Letvin N.L., Mascola J.R., Sun Y., Gorgone D.A., Buzby A.P., Xu L., et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006, 312:1530-1533.
72. Reimann K.A., Parker R.A., Seaman M.S., Beaudry K., Beddall M., Peterson L., et al. Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol 2005, 79:8878-8885.
73. de Groot N.G., Heijmans C.M.C., Koopman G., Verschoor E.J., Bogers W.M., Bontrop R.E. TRIM5 allelic polymorphism in macaque species/populations of different geographic origins: its impact on SIV vaccine studies. Tissue Antigens 2011, 78:256-262.
74. Klatt N.R., Harris L.D., Vinton C.L., Sung H., Briant J.A., Tabb B., et al. Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol 2010, 3:387-398.
75. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200:749-759.
76. Mehandru S., Poles M.A., Tenner-Racz K., Horowitz A., Hurley A., Hogan C., et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004, 200:761-770.
77. Guadalupe M., Reay E., Sankaran S., Prindiville T., Flamm J., McNeil A., et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003, 77:11708-11717.
78. Brenchley J.M., Price D.A., Schacker T.W., Asher T.E., Silvestri G., Rao S., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.